Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS)

Author(s): Esther Natalie Oliva, MD¹; Marta Riva, MD²; Pasquale Niscola, MD³; Valeria Santini, MD⁴; Massimo Breccia, MD⁵; Valentina Giai, MD⁶; Antonella Poloni, MD⁷; Andrea Patriarca, MD⁸; Elena Crisà, MD⁹; Isabella Capodanno, MD¹⁰; Prassede Salutari, MD¹¹; Gianluigi Reda, MD¹²; Nicola Cascavilla, MD¹³; Dario Ferrero, MD¹⁴; Attilio Guarini, MD¹⁵; Giovanni Tripepi, PhD¹⁶; Giuseppe Iannì, BSc¹⁷; Emilio Russo, PhD¹⁸; Andrea Castelli, MD¹⁹; Bruno Fattizzo, MD^12,20; Germana Beltrami, MD²¹; Monica Bocchia, MD²²; Alfredo Molteni, MD²³; Pierre Fenaux, MD²⁴; Ulrich Germing, MD²⁵; Alessandra Ricco, MD²⁶; Giuseppe A. Palumbo, MD, PhD²⁷; Stefana Impera, MD²⁸; Nicola Di Renzo, MD²⁹; Flavia Rivellini, MD³⁰; Francesco Buccisano, MD³¹; Aspasia Stamatoullas-Bastard, MD³²; Anna Marina Liberati, MD³³; Anna Candoni, MD³⁴; Ilaria Maria Delfino, BSc¹; Maria Teresa Arcadi, BSc³⁵; Patrizia Cufari, BSc¹; Lorenzo Rizzo, MD³⁶; Irene Bova, BSc³⁷; Maria Grazia D’Errigo, BSc³⁷; Gina Zini, MD38,³⁹; and Roberto Latagliata, MD⁴⁰

Source: DOI: 10.1200/JCO.22.02699 Journal of Clinical Oncology 41, no. 28 (October 01, 2023) 4486-4496.

Dr. Anjan Patel's Thoughts

This great Italian study uses eltrombopag in patients with low/intermediate risk MDS. The intervention arm had significantly fewer minor bleeding events and better platelet counts that were durable. Those with higher baseline Hb’s seemed to respond better to therapy, particularly if the Hb was >8g/dL. AML evolution/blast progression was not more common in the treatment arm, which refutes some prior concerns.

PURPOSE

In myelodysplastic syndromes (MDS), severe thrombocytopenia is associated with poor prognosis. This multicenter trial presents the second-part long-term efficacy and safety results of eltrombopag in patients with low-risk MDS and severe thrombocytopenia.

METHODS

In this single-blind, randomized, placebo-controlled, phase-II trial of adult patients with International Prognostic Scoring System low- or intermediate-1-risk MDS, patients with a stable platelet (PLT) count (<30 × 103/mm3) received eltrombopag or placebo until disease progression. Primary end points were duration of PLT response (PLT-R; calculated from the time of PLT-R to date of loss of PLT-R, defined as bleeding/PLT count <30 × 103/mm3 or last date in observation) and long-term safety and tolerability. Secondary end points included incidence and severity of bleeding, PLT transfusions, quality of life, leukemia-free survival, progression-free survival, overall survival and pharmacokinetics.

RESULTS

From 2011 to 2021, of 325 patients screened, 169 patients were randomly assigned oral eltrombopag (N = 112) or placebo (N = 57) at a starting dose of 50 mg once daily to maximum of 300 mg. PLT-R, with 25-week follow-up (IQR, 14-68) occurred in 47/111 (42.3%) eltrombopag patients versus 6/54 (11.1%) in placebo (odds ratio, 5.9; 95% CI, 2.3 to 14.9; P < .001). In eltrombopag patients, 12/47 (25.5%) lost the PLT-R, with cumulative thrombocytopenia relapse-free survival at 60 months of 63.6% (95% CI, 46.0 to 81.2). Clinically significant bleeding (WHO bleeding score ≥ 2) occurred less frequently in the eltrombopag arm than in the placebo group (incidence rate ratio, 0.54; 95% CI, 0.38 to 0.75; P = .0002). Although no difference in the frequency of grade 1-2 adverse events (AEs) was observed, a higher proportion of eltrombopag patients experienced grade 3-4 AEs (χ2 = 9.5, P = .002). AML evolution and/or disease progression occurred in 17% (for both) of eltrombopag and placebo patients with no difference in survival times.

CONCLUSION

Eltrombopag was effective and relatively safe in low-risk MDS with severe thrombocytopenia. This trial is registered with ClinicalTrials.gov identifier: NCT02912208 and EU Clinical Trials Register: EudraCT No. 2010-022890-33.

Author Affiliations

¹U.O.C. Ematologia, Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Reggio di Calabria, Italy; ²Dipartimento di Ematologia, Ospedale Niguarda Ca’ Granda, Milano, Italy; ³U.O. di Ematologia, Ospedale Sant’Eugenio, Roma, Italy; ⁴U.O. di Ematologia, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy; ⁵Dipartimento di Ematologia Policlinico Umberto I, Università La Sapienza, Roma, Italy; ⁶S.C. a Direzione Universitaria di Ematologia A.O., SS. Antonio e Biagio e Cesare Arrigo Alessandria, Alessandria, Italy; ⁷Clinica di Ematologia Azienda Ospedaliera Universitaria—Ospedali Riuniti di Ancona, Ancona, Italy; ⁸AOU Maggiore della Carità, Novara, Italy; ⁹Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy; ¹⁰U.O. di Ematologia, A.U.S.L.-IRCCS di Reggio Emilia, Reggio Emilia, Italy; ¹¹Dipartimento Oncologico-Ematologico, Ospedale Civile Spirito Santo, Pescara, Italy; ¹²Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy; ¹³U.O. Ematologia Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy; ¹⁴Dipartimento Biotecnologie Molecolari, Ematologia Universitaria A.O.U. Citta’ della Salute e della Scienza di Torino, Turin, Italy; ¹⁵U.O. Ematologia I.R.C.C.S. Istituto Tumori “Giovanni Paolo II”, Bari, Italy; ¹⁶IFC-CNR Institute of Clinical Physiology, Reggio Calabria, Italy; ¹⁷Dielnet SRL—CRO Reggio Calabria, Reggio Calabria, Italy; ¹⁸Department of Pharmacology, University of Germaneto Catanzaro, Catanzaro, Italy; ¹⁹SSD Ematologia Ospedale degli Infermi, Biella, Italy; ²⁰Dipartimento di Oncologia ed Emato-Oncologia, Università degli Studi di Milano, Milan, Italy; ²¹U.O. Ematologia e terapie cellulari, IRCCS Azienda Ospedaliera Universitaria San Martino, Genova, Italy; ²²UOC Ematologia, Università di Siena, Azienda Ospedaliera Universitaria Senese, Siena, Italy; ²³Divisione di Ematologia, ASST di Cremona, Cremona, Italy; ²⁴Groupe Francais desmyélodysplasies (GFM), Paris, France; ²⁵Department of Hematology, Oncology, and Clinical Immunology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany; ²⁶U.O. Ematologia con Trapianto, Azienda Ospedale Policlinicodi Bari, Bari, Italy; ²⁷Dipartimento di Scienze Mediche Chirurgiche e Tecnologie Avanzate “G.F. Ingrassia”, University of Catania, Catania, Italy; ²⁸U.O. C. Ematologia, A. O.ad Alta Specializzazione Ospedale Garibaldi Nesima, Catania, Italy; ²⁹U.O. di Ematologia, Ospedale Vito Fazzi, Lecce, Italy; ³⁰Divisione Ematologia, P.O. A. Tortora di Pagani-ASL Salerno, Pagani, Italy; ³¹Divisione di Biopatologia e Diagnostica per Immagini, Policlinico Universitario Tor Vergata, Rome, Italy; ³²Centre Henri Becquerel, Rue d’Amiens, Rouen, France; ³³S.C. Oncoematologia, Università degli Studi di Perugia A.O. Santa Maria, Terni, Italy; ³⁴Divisione Ematologia, P.O. Santa Maria della Misericordia, A.S.U.F.C di Udine, Udine, Italy; ³⁵U.O. Farmacia Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Reggio di Calabria, Italy; ³⁶Dipartimento di Ematologia, Ospedale Niguarda Ca’ Granda, Milan, Italy; ³⁷U.O.S. di Genetica Medica Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Reggio di Calabria, Italy; ³⁸Fondazione Policlinico, Universitario A. Gemelli IRCCS, Rome, Italy; ³⁹Università Cattolica del Sacro Cuore, Rome, Italy; ⁴⁰Divisione di Ematologia, Ospedale Belcolle, Viterbo, Italy

A Novel Anti-CD38 Monoclonal Antibody for Treating Immune Thrombocytopenia

This is a promising new agent for ITP, where the median time of 50K platelets is one week. This is a small study though, awaiting more data in the future.

Prolonged response after TPO-RA discontinuation in primary ITP: results of a prospective multicenter study

Benign heme article of the month– A significant portion of patients with stable platelet counts can be gently tapered from TPO-agonists. Those who needed to be re-challenged had a good response. This is likely an underutilized strategy.

The role of CD8+ T-cell clones in immune thrombocytopenia

Thought provoking article regarding a non-antibody mediated mechanism in chronic ITP.

Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes

New criteria for response to therapy in high grade MDS, focuses on pt centered outcomes.

Introduction to a How I Treat series on management of high-risk patients following allogeneic transplant

Interesting prospective study assessing outcomes in ITP in pregnant women while measuring neonatal ITP in the developing child, with a control of non-pregnant women for comparison. Pregnancy-ITP was associated with a 2.7x higher rate of recurrent disease. However, bleeding was similar in pregnant vs. non-pregnant women. NITP risk was associated with more severe ITP disease in the mother and the severity of the disease, as well as prior h/o ITP in the mother.